SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX is drawing attention after reaching a 52-week high ahead of an expected Q3 report, with traders watching BRIUMVI sales and whether results support the rally. Buyout speculation and possible short covering are also prominent, but the acquisition talk is unconfirmed and some traders attribute the strength to the companys operating momentum instead.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons quarterly results and heavy AI infrastructure spending drove debate, as investors weighed weaker-than-expected results and sharply negative free cash flow against accelerating AWS growth and its outlook. Traders were split between concerns that cash burn and rising investment could pressure the stock and dip-buyers who viewed the initial selloff as overdone; shares rebounded substantially from their lows.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Better-than-expected quarterly results and strength in parks and streaming have renewed optimism, with traders pointing to analyst upgrades and a potential technical breakout. Others remain skeptical, citing Disneys long-running share-price stagnation and resistance levels.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intels steep drop followed weak forward guidance despite a solid quarter, with traders focused on softer PC demand, manufacturing constraints and analyst downgrades; the pressure also fed into a broader semiconductor and tech selloff. The community is split between calling the reaction excessive and buying the dip, and warning that the outlook and execution problems could prolong the decline.

United States Natural Gas Fund LP. - United States Natural Gas Fund

United States Natural Gas Fund, LP

UNG is drawing attention as natural gas prices slide amid mild-weather forecasts that point to weaker heating demand, with surplus inventories adding pressure. Traders are split between buying the decline ahead of winter and expecting further weakness if warm conditions persist; colder forecasts or storage data are seen as potential catalysts for a shift.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit is drawing attention ahead of the November 14 FDA decision on ivonescimab plus chemotherapy for EGFR-mutated lung cancer, with traders weighing the Phase 3 results and recent positive biliary-cancer data against regulatory concerns, including the lack of statistically significant overall-survival results. Bulls see approval potential and broader promise for the drug, while skeptics stress that the decision remains uncertain and could hinge on FDA concerns about the trial population or manufacturing.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Attention centers on the upcoming FDA decision on Capricors deramiocel for Duchenne muscular dystrophy, with traders focusing on the amended upper-limb-function data and recent rare-disease discussions. New commercial-launch job postings and other FDA approvals have fueled optimism about a favorable decision, while skeptics caution that neither hiring nor regulatory flexibility guarantees approval and debate the risk of a CRL; some also attribute price swings to short covering or rumors of a leak.

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Agenus Inc

Agenuss BOT+BAL combination drew attention after Phase 2 NEOASIS data at ESMO showed strong pathologic responses in a small dMMR colon cancer cohort, alongside discussion of sarcoma results. Traders called the findings encouraging but debated their significance given the small, early-stage studies and awaited Phase 3 confirmation, while some questioned why the share price weakened despite the data and raised dilution and execution concerns.

Hedera (HBAR) is a cryptocurrency launched in 2017. Hedera has a current supply of 50,000,000,000 with 44,327,155,828.93500734 in circulation. The last known price of Hedera is 0.07221819 USD and is up 4.74 over the last 24 hours. It is currently trading on 465 active market(s) with $92,347,671.42 traded over the last 24 hours. More information can be found at https://www.hedera.com/.

Hedera Hashgraph

HBARs sharp rally and elevated volume are being linked by traders to IBM-related cloud news and Hederas reported connections to NVIDIAs AI safety platform. Enthusiasm over enterprise and AI use cases is tempered by profit-taking and skepticism that the announcements will translate into meaningful adoption or token demand.

Cameco Corp. engages in the provision of uranium. It operates through the following segments: Uranium and Fuel Services. The Uranium segment is involved in the exploration for, mining, milling, purchase, and sale of uranium concentrate. The Fuel Services segment deals with the refining, conversion, and fabrication of uranium concentrate and the purchase and sale of conversion services. The company was founded in 1988 and is headquartered in Saskatoon, Canada.

Cameco Corp.

Camecos Q3 report and narrower 2026 production guidance are driving the selloff, with traders focusing on weaker results and production setbacks, including at Cigar Lake. Some see the report as disappointing and the stock as overvalued, while long-term bulls point to firm uranium prices and nuclear demand.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple Myeloma

$2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple Myeloma $2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple MyelomaPR NewswireTEL...

Weekly Losses Deepen As Small Caps Lag And Yields Edge Higher Into Earnings Gauntlet

Weekly Losses Deepen As Small Caps Lag And Yields Edge Higher Into Earnings Gauntlet Weekly Losses Deepen As Small Caps Lag And Yields Edge Higher Into Earnings GauntletPR NewswireNEW YORK, Oct. 1, 2026Stock Preachers News CommentaryNEW YORK, Oct. 1, 2026 /PRNewswire/ --Stocks closed out a choppy...

RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results

RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial ResultsPR NewswireTEL AVIV, Israel and RALEIGH, N.C., Sept. 30, 2026Executing a full strategic portfolio reset, RedHill is now a...

12 Health Care Stocks Moving In Monday's Intraday Session

Gainers

Redhill Biopharma (NASDAQ:RDHL) stock increased by 69.4% to $1.12 during Monday's regular session. The company's market cap stands at $4.0 million.
CollPlant Biotechnologies (NASDAQ:CLGN) sharesread more...

Pharma Junior Rallies 66% as Asset Monetization Unlocks $18M Upfront Cash

An upfront cash infusion from a commercial asset sale sparked a massive morning rally in specialty pharma today, highlighting how non-dilutive liquidity events can rapidly re-rate microcap balance sheets. When a developer monetizes its majority stake in an approved drug to a global manufacturing partner, the market quickly rewards the immediate cash injection. RedHill Biopharma Ltd. (Nasdaq: RDHL) advanced Monday after divesting its Talicia business to a subsidiary of Apotex Health Corp. (TSX: APTX) for $18M in cash upfront, plus up to additional $35M tied to worldwide net-sales ...

Redhill Biopharma Stock Doubles In One Session  Here's Why

RedHill Biopharma divests Talicia to Apotex, boosting liquidity and funding its commercial growth strategy and RHB-102 development.read more...

RedHill Cashes Out of Talicia: $18M Upfront Deal Hands H. pylori Franchise to Apotex and Funds a GI Reset

RedHill Biopharma (NASDAQ:RDHL) just sold the product that defined its U.S. commercial identity. RedHill announced it divested its remaining 70% stake in Talicia to a subsidiary of newly public Apotex Health (TSX:APTX) for $18 million in cash upfront plus up to $35 million in worldwide net sales milestones. Apotex already owned the other 30% after buying Cumberland’s (NASDAQ:CPIX) U.S. branded business earlier this year. The sale consolidates Talicia under one owner and gives RedHill the liquidity it says it needs to rebuild a larger gastrointestinal franchise.

12 Health Care Stocks Moving In Monday's Pre-Market Session

Gainers

Redhill Biopharma (NASDAQ:RDHL) shares increased by 96.7% to $1.3 during Monday's pre-market session. The market value of their outstanding shares is at $4.0 million.
Vivos Therapeutics (NASDAQ:VVOS) stockread more...

Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development

Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development PR Newswire TEL AVIV, Israel and RALEIGH, N.C., July 28, 2026 The number of confirmed Ebola cases and...

RedHill Biopharma Ltd. engages in the development and commercialization of drugs for gastrointestinal (GI), infectious diseases, and oncology. The firm's products include Talicia, Movantik, and Aemcolo. It operates through the Commercial Operations and Research and Development segments. The Commercial Operations segment covers areas relating to commercial sales through a subsidiary in the United States. The Research and Development segment includes the study and licensing of therapeutic candidates. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.

Redhill Biopharma Ltd. - ADR

RedHill Biopharma Logs Best Session In Over A Year After $10M Legal Victory — Retail Sees Bullish Triggers Ahead

Equity

Bearish Sentiment

RedHill Biopharma’s&nbsp;stock recorded its best trading session in more than a year on Monday after the New York Supreme Court upheld a $10 million award in the company’s ongoing legal dispute with Kukbo.Shares of the company jumped 27.2%, to close at $2.34 on Monday, before slipping 7.1% to $2.17 in after-hours trading.The Court reaffirmed its original summary judgment ruling in favor of RedHill, dismissing Kukbo’s appeal and the entirety of its defense. It ruled that Kukbo breached both the subscription and exclusive license agreements signed with RedHill in 2021 and 2022 and that RedHill had properly fulfilled its obligations, even after Kukbo’s non-payment.The total award amounts to approximately $10 million,&nbsp;comprising the original judgment of $8.25 million and an additional $1.82 million granted in August 2025 for legal costs and expenses. Both awards carry a 9% ongoing statutory interest accrual. Kukbo retains the right to further appeal the ruling.In addition to the U.S. court ruling, RedHill also secured a court-ordered seizure of Kukbo’s assets in May 2025 from Korea’s Incheon District Court, freezing those assets following the initial $8.25 million award and preventing their disposal before judgment enforcement. In August, RedHill received an additional $1.82 million for legal expenses.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 9,900% surge in 24-hour message volume.One user stated that short sellers were likely to get squeezed, arguing that RedHill’s market capitalization of approximately $7 million was significantly below the $10 million court award and calling the stock undervalued, with a fair price between $5 and $7.<stembedurl>https://stocktwits.com/PeterTauscher/message/630386393</stembedurl>Another user reported an increase in their position, noting that several potential catalysts could drive the stock higher in the coming months.<stembedurl>https://stocktwits.com/Imatron12/message/630390832</stembedurl><a href="https://stocktwits.com/symbol/RDHL">RedHill Biopharma’s stock</a> has declined 62.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

RedHill Biopharma’s stock (RDHL) has declined 62.3% so far in 2025. (Photo credit: Getty Images)

The stock rallied after the New York Supreme Court reaffirmed RedHill’s $10 million award in its dispute with Kukbo.

RedHill Biopharma Ltd.

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

$RDHL $2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple Myeloma

Day Trader

$RDHL What about transparency? What about business progress or updates? Why aren't there updates on sales—if any—of the new products? As long as the situation remains this way, extending the 180-day period won't help.

Yoni

$RDHL Something very strange: 
Even after a positive announcement that it is receiving money, 
the stock isn't rising enough.

$RDHL Should I back Zuckerberg, Musk or Ben-Asher? All cost me the same in terms of transaction fee…

Zaki Sabir

$RDHL What’s going to happen with the drop in share price? This company couldn't care less about its shareholders; the question is whether there's any chance of breaking past the $1 mark.

$RDHL Hyloris reports that it has more than 30 products and candidates competing for capital and management attention. Management explains that it has begun concentrating resources on programs with clearer prospects for regulatory approval, commercial launches and recurring income. Hyloris is not operating with unlimited resources. more significantly, the company decided in September 2026 to discontinue two other development programs and stop the XTRAZA Phase 3 trial and further U.S. development.

Henry

$RDHL it is the same exact word salad they used a few months ago regarding this. It is a nothing burger they are great at putting out PR's that amount to nothing.

Feed

News

Sentiment

Fundamentals

Info

RDHL RedHill Biopharma Ltd.

Fundamentals

Latest RDHL News